Geode Capital Management LLC Purchases 22,881 Shares of Annovis Bio, Inc. (NYSE:ANVS)

Geode Capital Management LLC raised its position in Annovis Bio, Inc. (NYSE:ANVSFree Report) by 30.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 99,114 shares of the company’s stock after buying an additional 22,881 shares during the period. Geode Capital Management LLC’s holdings in Annovis Bio were worth $799,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. State Street Corp grew its position in Annovis Bio by 23.7% during the third quarter. State Street Corp now owns 36,035 shares of the company’s stock valued at $290,000 after buying an additional 6,900 shares during the period. Greenwich Wealth Management LLC boosted its stake in Annovis Bio by 19.9% in the second quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company’s stock valued at $87,000 after acquiring an additional 2,500 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Annovis Bio during the 2nd quarter valued at approximately $115,000. Finally, Quest Partners LLC purchased a new stake in shares of Annovis Bio during the 3rd quarter worth approximately $371,000. Institutional investors own 15.83% of the company’s stock.

Annovis Bio Price Performance

Annovis Bio stock opened at $4.90 on Friday. The firm has a market capitalization of $67.61 million, a P/E ratio of -1.10 and a beta of 1.64. Annovis Bio, Inc. has a one year low of $4.21 and a one year high of $20.00. The business has a fifty day moving average price of $6.10 and a 200-day moving average price of $8.02.

Annovis Bio (NYSE:ANVSGet Free Report) last issued its earnings results on Friday, November 8th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.33). Sell-side analysts expect that Annovis Bio, Inc. will post -2.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANVS has been the topic of several research analyst reports. Maxim Group upgraded Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Friday, October 25th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Annovis Bio in a report on Monday, November 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $31.40.

Check Out Our Latest Analysis on ANVS

Annovis Bio Profile

(Free Report)

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.

Featured Stories

Want to see what other hedge funds are holding ANVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annovis Bio, Inc. (NYSE:ANVSFree Report).

Institutional Ownership by Quarter for Annovis Bio (NYSE:ANVS)

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.